Safety and effectiveness of intravenous remidazolam sedation and propofol sedation in MRI examination of children

Application of remidazolam sedation in children's magnetic resonance imaging

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500097093

Enrollment

Unknown

Registered

2025-02-12

Start date

2023-01-04

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric outpatient sedation

Interventions

Propofol group: intravenous bolus of Propofol: 3mg/kg

Remazolam group:intravenous bolus of Remimazolam: 0.4mg/kg

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Age 1-6 years old; (2) ASAI or II level; (3) Proposed head MRI examination; (4) The family members of the sick child sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria:(1)allergy to benzodiazepines or propofol; (2)significant dysfunction of key organs such as the heart, liver, or kidneys;(3) presence of a difficult airway; (4) participation in other clinical trials within the past three months.

Design outcomes

Primary

Measure	Time frame
Rate of Successful Sedation;	—

Secondary

Measure	Time frame
???? Adverse reactions;Induction Time;Recovery Time ;	—

Countries

China

Contacts

Public ContactYan Jian'e

Lianyungang Maternal and Child Health Hospital

672694832@qq.com+86 180 3662 6197

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026